Clinical Trial Update: Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

This Phase 3 trial compared ABT-874 to Etanercept and placebo in adults with moderate to severe chronic plaque psoriasis; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ABT-874 (briakinumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Moderate to Severe Plaque Psoriasis | Phase 3 | Status: COMPLETED